Certara (CERT) Stock Forecast & Price Target

Certara is well-positioned to capitalize on the increasing demand for biosimulation software and services in the healthcare industry as it offers a unique and differentiated technology that speeds up drug discovery and development processes. With a strong presence in key markets and a diverse product portfolio, Certara has been able to achieve strong financial results, with a 35% year-over-year growth in Gold Equivalent Ounces and a projected combined value of $519.4 million for the firm. The recent divestiture of the R&MW division has allowed Certara to focus more on its core MIDD and AI platforms, leading to a potential improvement in margins and revenue growth in the future.

Certara is facing several challenges in the near term, including a mixed 1Q26 performance, divestiture of the regulatory and medical writing business resulting in lower revenue growth expectations for FY26, and a lack of major financial unlock despite sharpened focus on core areas. Additionally, market volatility and headwinds in key markets such as Asia and a potential passive selling pressure may further impact Certara's financials and stock value. These risks, combined with the slow pace of regulatory approvals, make for a negative outlook on Certara's stock.